- 2024 year
- 2023 year
- 2022 year
- 2021 year
- 2020 year
- 2019 year
- 2018 year
- 2017 year
- 2016 year
- 2015 year
- 2014 year
- 2013 year
- 2012 year
Health is the lack of internal interference for life
Contacts
"Liveriya® IC» - a new position in the "InterChem" portfolio
The drug "Liveriya® IC" replenished arsenal of hepatoprotective drugs.
The liver - a vital organ, which plays an important role in metabolism. Neutralization of toxins entering the blood from the gastrointestinal tract occurs in the liver. The liver synthesized most important protein substances of the blood, formed glycogen and bile.
The main causes of chronic liver disease are hepatotropic viruses, disorders of lipid and carbohydrate metabolism, acute and chronic alcohol or medicinal intoxication. High incidence of liver disease in recent years due to the significant increase in the number of patients with obesity, diabetes, metabolic syndrome. Fibrosis and cirrhosis of the liver - a natural outcome of chronic hepatitis B, regardless of its cause factors.
When hepatoprotective funds are sufficiently represented in the market, the arsenal of hindering the development of liver fibrosis, yet not so wide. One of the drugs which have such effects is "Liveriya® IC". "Liveriya® ІC" prevents the death of hepatocytes, and prevents the development of fatty liver, has hepatoprotective, detoxification and anti-alcoholic effect:
The liver - a vital organ, which plays an important role in metabolism. Neutralization of toxins entering the blood from the gastrointestinal tract occurs in the liver. The liver synthesized most important protein substances of the blood, formed glycogen and bile.
The main causes of chronic liver disease are hepatotropic viruses, disorders of lipid and carbohydrate metabolism, acute and chronic alcohol or medicinal intoxication. High incidence of liver disease in recent years due to the significant increase in the number of patients with obesity, diabetes, metabolic syndrome. Fibrosis and cirrhosis of the liver - a natural outcome of chronic hepatitis B, regardless of its cause factors.
When hepatoprotective funds are sufficiently represented in the market, the arsenal of hindering the development of liver fibrosis, yet not so wide. One of the drugs which have such effects is "Liveriya® IC". "Liveriya® ІC" prevents the death of hepatocytes, and prevents the development of fatty liver, has hepatoprotective, detoxification and anti-alcoholic effect:
- Activates alcoholdehydrogenase and acetaldehydedehydrogenase to accelerate the process of withdrawal of ethanol and acetaldehyde from the body and reduces their toxic effects.
- Increases resistance of hepatocytes to the products of lipid peroxidation induced by exposure to various toxic agents, particularly ethanol.
- Prevents the accumulation of fat in hepatocytes, which prevents the formation of fatty liver.
- It prevents the formation of fibronectin and collagen that inhibits the formation of cirrhosis.